161 related articles for article (PubMed ID: 35429302)
61. Mining featured biomarkers associated with vascular invasion in HCC by bioinformatics analysis with TCGA RNA sequencing data.
Zhang R; Ye J; Huang H; Du X
Biomed Pharmacother; 2019 Oct; 118():109274. PubMed ID: 31545220
[TBL] [Abstract][Full Text] [Related]
62. Osteopontin increases hepatocellular carcinoma cell growth in a CD44 dependant manner.
Phillips RJ; Helbig KJ; Van der Hoek KH; Seth D; Beard MR
World J Gastroenterol; 2012 Jul; 18(26):3389-99. PubMed ID: 22807608
[TBL] [Abstract][Full Text] [Related]
63. An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma.
Takafuji V; Forgues M; Unsworth E; Goldsmith P; Wang XW
Oncogene; 2007 Sep; 26(44):6361-71. PubMed ID: 17452979
[TBL] [Abstract][Full Text] [Related]
64. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
[TBL] [Abstract][Full Text] [Related]
65. Significance of plasma osteopontin in diagnosis of hepatitis C virus-related hepatocellular carcinoma.
Nabih MI; Aref WM; Fathy MM
Arab J Gastroenterol; 2014; 15(3-4):103-7. PubMed ID: 25249230
[TBL] [Abstract][Full Text] [Related]
66. Fanconi Anemia Complementation Group E, a DNA Repair-Related Gene, Is a Potential Marker of Poor Prognosis in Hepatocellular Carcinoma.
Takahashi J; Masuda T; Kitagawa A; Tobo T; Nakano Y; Abe T; Ando Y; Kosai K; Kobayashi Y; Matsumoto Y; Yoshizumi T; Mori M; Mimori K
Oncology; 2022; 100(2):101-113. PubMed ID: 34724663
[TBL] [Abstract][Full Text] [Related]
67. Identification of Potential Gene Network Associated with HCV-Related Hepatocellular Carcinoma Using Microarray Analysis.
Cheng Y; Ping J; Chen J
Pathol Oncol Res; 2018 Jul; 24(3):507-514. PubMed ID: 28669080
[TBL] [Abstract][Full Text] [Related]
68. Bioinformatics Analysis of Prognostic Tumor Microenvironment-Related Genes in the Tumor Microenvironment of Hepatocellular Carcinoma.
Tian Z; Wang Z; Chen Y; Qu S; Liu C; Chen F; Ma L; Zhu J
Med Sci Monit; 2020 Mar; 26():e922159. PubMed ID: 32231177
[TBL] [Abstract][Full Text] [Related]
69. Screening Hub Genes as Prognostic Biomarkers of Hepatocellular Carcinoma by Bioinformatics Analysis.
Zhou Z; Li Y; Hao H; Wang Y; Zhou Z; Wang Z; Chu X
Cell Transplant; 2019 Dec; 28(1_suppl):76S-86S. PubMed ID: 31822116
[TBL] [Abstract][Full Text] [Related]
70. Serum anti-osteopontin autoantibody as a novel diagnostic and prognostic biomarker in patients with hepatocellular carcinoma.
Ying X; Zhao Y; Wang JL; Zhou X; Zhao J; He CC; Guo XJ; Jin GH; Wang LJ; Zhu Q; Han SX
Oncol Rep; 2014 Oct; 32(4):1550-6. PubMed ID: 25109745
[TBL] [Abstract][Full Text] [Related]
71. Systematic summarization of the expression profiles and prognostic roles of the dishevelled gene family in hepatocellular carcinoma.
Mei J; Yang X; Xia D; Zhou W; Gu D; Wang H; Liu C
Mol Genet Genomic Med; 2020 Sep; 8(9):e1384. PubMed ID: 32588988
[TBL] [Abstract][Full Text] [Related]
72. Identification of CELSR2 as a novel prognostic biomarker for hepatocellular carcinoma.
Xu M; Zhu S; Xu R; Lin N
BMC Cancer; 2020 Apr; 20(1):313. PubMed ID: 32293343
[TBL] [Abstract][Full Text] [Related]
73. M2-like tumor-associated macrophage-related biomarkers to construct a novel prognostic signature, reveal the immune landscape, and screen drugs in hepatocellular carcinoma.
Qu X; Zhao X; Lin K; Wang N; Li X; Li S; Zhang L; Shi Y
Front Immunol; 2022; 13():994019. PubMed ID: 36177006
[TBL] [Abstract][Full Text] [Related]
74. Weighted correlation gene network analysis reveals a new stemness index-related survival model for prognostic prediction in hepatocellular carcinoma.
Zhang Q; Wang J; Liu M; Zhu Q; Li Q; Xie C; Han C; Wang Y; Gao M; Liu J
Aging (Albany NY); 2020 Jul; 12(13):13502-13517. PubMed ID: 32644941
[TBL] [Abstract][Full Text] [Related]
75. HCCDB: A Database of Hepatocellular Carcinoma Expression Atlas.
Lian Q; Wang S; Zhang G; Wang D; Luo G; Tang J; Chen L; Gu J
Genomics Proteomics Bioinformatics; 2018 Aug; 16(4):269-275. PubMed ID: 30266410
[TBL] [Abstract][Full Text] [Related]
76. Identification of biomarkers for Barcelona Clinic Liver Cancer staging and overall survival of patients with hepatocellular carcinoma.
Xu W; Rao Q; An Y; Li M; Zhang Z
PLoS One; 2018; 13(8):e0202763. PubMed ID: 30138346
[TBL] [Abstract][Full Text] [Related]
77. Overexpression of EWSR1 (Ewing sarcoma breakpoint region 1/EWS RNA binding protein 1) predicts poor survival in patients with hepatocellular carcinoma.
Jiang W; Wu T; Shi X; Xu J
Bioengineered; 2021 Dec; 12(1):7941-7949. PubMed ID: 34612781
[TBL] [Abstract][Full Text] [Related]
78. Prognostic value of aberrantly expressed methylation genes in human hepatocellular carcinoma.
Zhen L; Ning G; Wu L; Zheng Y; Yang F; Chen T; Xu W; Liu Y; Xie C; Peng L
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 32955083
[TBL] [Abstract][Full Text] [Related]
79. PPM1D is a potential prognostic biomarker and correlates with immune cell infiltration in hepatocellular carcinoma.
Yu Z; Song Y; Cai M; Jiang B; Zhang Z; Wang L; Jiang Y; Zou L; Liu X; Yu N; Mao X; Peng C; Liu S
Aging (Albany NY); 2021 Sep; 13(17):21294-21308. PubMed ID: 34470916
[TBL] [Abstract][Full Text] [Related]
80. Identification of immune-infiltrating cell-related biomarkers in hepatocellular carcinoma based on gene co-expression network analysis.
Hou Y; Zhang G
Diagn Pathol; 2021 Jul; 16(1):57. PubMed ID: 34218795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
